KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue (2020 - 2025)

Recursion Pharmaceuticals' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $114.0 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 4.0% year-over-year to $114.0 million; the TTM value through Dec 2025 reached $114.0 million, down 4.0%, while the annual FY2025 figure was $114.0 million, 4.0% down from the prior year.
  • Non-Current Deffered Revenue reached $114.0 million in Q4 2025 per RXRX's latest filing, up from $111.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $129.6 million in Q1 2025 to a low of $2.8 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $61.2 million, with a median of $51.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 3795.31% in 2022, then plummeted 69.42% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $6.7 million in 2021, then soared by 953.86% to $70.3 million in 2022, then decreased by 27.07% to $51.2 million in 2023, then surged by 131.79% to $118.8 million in 2024, then fell by 4.0% to $114.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Non-Current Deffered Revenue are $114.0 million (Q4 2025), $111.2 million (Q3 2025), and $126.2 million (Q2 2025).